Il-27 Impact on Nk Cells Activity: Implication for a Robust Anti-Tumor Response in Chronic Lymphocytic Leukemia

Il-27 Impact on Nk Cells Activity: Implication for a Robust Anti-Tumor Response in Chronic Lymphocytic Leukemia Publisher Pubmed

Hemati M^{1, 2} ; Rasouli Nejad Z^{1, 2} ; Shokri MR⁴ ; Ghahremanfard F¹ ; Mir Mohammadkhani M^{5, 6} ; Kokhaei P^{1, 3}

Show Affiliations

1. Cancer Research Center, Semnan University of Medical Sciences, Semnan, Iran
2. Student Research Committee, Semnan University of Medical Sciences, Semnan, Iran
3. Department of Oncology-Pathology, BioClinicum, Karolinska University Hospital Solna and Karolinska Institute, Stockholm, Sweden
4. Department of Immunology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran
5. Health Research Center of Semnan University of Medical Sciences, Semnan, Iran
6. Department of Epidemiology and Biostatistics, Semnan University of Medical Sciences, Semnan, Iran

Source: International Immunopharmacology Published:2020

Abstract

Interleukin 27 (IL-27) belongs to IL-12 cytokine family, has shown anti-tumor potential in several solid tumors, as well as hematologic malignancies. IL-27 can inhibit tumor growth and progression through direct and indirect mechanisms, such as inhibition of proliferation, angiogenesis, induction of apoptosis in tumor cells, and anti-tumor immune response. B-CLL is characterized by remarkable immune perturbation, which leads to disease complications and reduced effectiveness of the treatment. Natural killer cells (NK) are considered as an important arm for the elimination of transformed cells. However, NK cells have shown significant impairment in patients with CLL. Here we analyzed the activity of recombinant human (rh) IL-27-stimulated NK cells in bone marrow (BM) and peripheral blood (PB) of CLL patients using cell surface flow cytometry assessment, and cytotoxicity assay. We showed that rhIL-27 can increase CD69 on NK cells both in BM and PB. Interestingly, BM-NK cells treated with rhIL-27 exhibited a significant increase in degranulation and NK cell-mediated cytotoxicity as compared with untreated NK cells, whereas it did not improve NK cell activity of PB. These observations added further explanation to the anti-tumor activity of IL-27 and also could pave the way to adoption immunostimulatory adjuvant for therapies in CLL. © 2020 Elsevier B.V.

2. Dysregulated Expression of Tim-3 and Nkp30 Receptors on Nk Cells of Patients With Chronic Lymphocytic Leukemia, Oncology Research and Treatment (2019)

3. Natural Killer Cells and Acute Myeloid Leukemia: Promises and Challenges, Cancer Immunology# Immunotherapy (2022)

4. Natural Killer Cells and Their Exosomes in Viral Infections and Related Therapeutic Approaches: Where Are We?, Cell Communication and Signaling (2023)

5. The Effect of Thymoquinone on Peripheral Blood Mononuclear Cells (Pbmcs) Viability of Patients With B-Chronic Lymphocytic Leukemia, Koomesh (2023)

6. Natural Killer Cells and Cancer Therapy, What We Know and Where We Are Going, Immunotherapy (2019)

7. Mesenchymal Stem Cells and Natural Killer Cells Interaction Mechanisms and Potential Clinical Applications, Stem Cell Research and Therapy (2022)

Experts (# of related papers)

Nima Rezaei (2)

Ali Akbar Amirzargar (1)

Style	Citing Format
MLA	Hemati M, et al.. "Il-27 Impact on Nk Cells Activity: Implication for a Robust Anti-Tumor Response in Chronic Lymphocytic Leukemia." International Immunopharmacology, vol. 82, no. , 2020, pp. -.
APA	Hemati M, Rasouli Nejad Z, Shokri MR, Ghahremanfard F, Mir Mohammadkhani M, Kokhaei P (2020). Il-27 Impact on Nk Cells Activity: Implication for a Robust Anti-Tumor Response in Chronic Lymphocytic Leukemia. International Immunopharmacology, 82(), -.
Chicago	Hemati M, Rasouli Nejad Z, Shokri MR, Ghahremanfard F, Mir Mohammadkhani M, Kokhaei P. "Il-27 Impact on Nk Cells Activity: Implication for a Robust Anti-Tumor Response in Chronic Lymphocytic Leukemia." International Immunopharmacology 82, no. (2020): -.
Harvard	Hemati M et al. (2020) 'Il-27 Impact on Nk Cells Activity: Implication for a Robust Anti-Tumor Response in Chronic Lymphocytic Leukemia', International Immunopharmacology, 82(), pp. -.
Vancouver	Hemati M, Rasouli Nejad Z, Shokri MR, Ghahremanfard F, Mir Mohammadkhani M, Kokhaei P. Il-27 Impact on Nk Cells Activity: Implication for a Robust Anti-Tumor Response in Chronic Lymphocytic Leukemia. International Immunopharmacology. 2020;82():-.
BibTex	@article{ author = {Hemati M and Rasouli Nejad Z and Shokri MR and Ghahremanfard F and Mir Mohammadkhani M and Kokhaei P}, title = {Il-27 Impact on Nk Cells Activity: Implication for a Robust Anti-Tumor Response in Chronic Lymphocytic Leukemia}, journal = {International Immunopharmacology}, volume = {82}, number = {}, pages = {-}, year = {2020} }
RIS	TY - JOUR AU - Hemati M AU - Rasouli Nejad Z AU - Shokri MR AU - Ghahremanfard F AU - Mir Mohammadkhani M AU - Kokhaei P TI - Il-27 Impact on Nk Cells Activity: Implication for a Robust Anti-Tumor Response in Chronic Lymphocytic Leukemia JO - International Immunopharmacology VL - 82 IS - SP - EP - PY - 2020 ER -

Science Communicator Platform

Authors

Authors Affiliations

Abstract